Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors
The ABL kinase inhibitor imatinib has been used as front-line therapy for Philadelphia-positive chronic myeloid leukemia. However, a significant proportion of imatinib-treated patients relapse due to occurrence of mutations in the ABL kinase domain. Although inhibitor sensitivity for a set of mutati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-04-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317701643 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|